^
Association details:
| Biomarker: | FLT3 N676D + FLT3 Y842C |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Reversal of Acquired Drug Resistance in FLT3-mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
Excerpt:
...cells with compound mutations in both TKDs (e.g., the Ba/F3-ITD-Res and the engineered Ba/F3-ITD+676/842 cells) in addition to the ITD mutations displayed even greater resistance (EC50 of 4.2 ± 1.50 and 6.6 ± 0.53 μmol/L, respectively...
DOI:
https://dx.doi.org/10.1158%2F1078-0432.CCR-13-2052
